Cyclerion Therapeutics UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Well, thank you very much, everyone. We will get started. I am Michael Yee, Senior Biotechnology Analyst at UBS. Thank you for joining us on our next session. I am excited to have the President and CEO, Jonathan Violin, from Korsana Biosciences up here with us. Korsana has a very exciting blood-brain shuttle technology platform, and the lead program is an A-beta TfR, a blood-brain shuttle candidate that is very exciting for the treatment of Alzheimer's disease. Jonathan, if I may give you an opportunity to just tell us a little bit about Korsana, the platform technology, and why you think it could be better than other platform blood-brain shuttle technologies, and then maybe we can delve into some of the questions.
Sure. Thank you very much for having us here.
Absolutely. Real pleasure to join you.
We founded Korsana because we see a huge opportunity in Alzheimer's disease. We have the first two disease-modifying therapies approved, and yet they leave a lot to be desired in terms of their clinical performance, their safety, tolerability, convenience. Now Roche, to their great credit, I think has really broken open the field in terms of what is next. Their trontinemab, which is a shuttled version of gantenerumab. So, took an antibody that binds and clears plaque and attached it to a moiety that binds to the transferrin receptor in the right way, and we will probably talk more about that increases access to the brain, crosses the blood-brain barrier, that delivers faster, deeper plaque clearance, dramatically reduced rates of ARIA, so a better therapeutic profile. But in our view, it is not the end of the road. It is intravenous. Patients need to be pretreated with corticosteroids because of high rate of infusion-related reactions, and there is a modest rate of anemia, 10% or 20% rate of anemia in the phase I/II study.
We think there is more to do in this space, and so we designed our lead molecule, KRSA-028, in partnership with Paragon Therapeutics, in a way that we think can deliver what we hope will be best-in-class profile.
Fantastic. I agree with you. Obviously, we have total proof of concept validation, FDA-approved drugs from first generation, I say first generation just because they are approved, A-beta antibody products from Biogen and Lilly, and they are on pace to do $1 billion and growing, but they do have liabilities. You guys are enhancing upon that by using the TfR, the transferrin receptor, to shuttle an A-beta program through. I appreciate it is from Paragon Labs. Can you describe the profile of the candidate before we get into the data? What has been enhanced on your antibody? Is it a better A-beta antibody? Is the TfR fragment better? Is your overall construct better than Roche trontinemab?
We designed KRSA-028 from scratch, thinking about all the parameters that could make it very difficult to beat, that could deliver a best-in-class profile. I will walk through the individual components. In terms of the IgG backbone, the amyloid binding component, our molecule is selective for pyroglutamate forms of amyloid, so that is a post-translational modification that is enriched in plaque. You can think of this as more plaque selective. That would put it in the same category as donanemab, Kisunla from Lilly, or their next gen, remternetug, which at least numerically clear plaque a little faster and numerically a little better slowing of cognitive decline. We thought given the existing clinical data, that was the place to start, was targeting pyroglutamate amyloid. That is the IgG backbone. The shuttle, the portion that binds the transferrin receptor, well, it is a different sequence.
Pharmacologically, it operates very similarly to the trontinemab shuttle, and that is by design. What trontinemab has taught us, and this is the culmination of two or three decades of work on how to design these shuttles, it is not just the target that matters, the transferrin receptor. Epitope matters. We do not want to disrupt transferrin binding, otherwise you disrupt iron homeostasis. Affinity matters. If it binds too loosely, nothing gets shuttled. If it binds too tightly, it gets stuck. There is a bell-shaped dose response curve. When we looked at the trontinemab data, the shuttling component itself we think works great. There are other features, which I will talk about in a moment, where we thought we could deliver differentiation. Our shuttle, while it is a different sequence, same target, same epitope, nearly the same affinity as trontinemab for the transferrin receptor.
Where some of the differentiation comes in then is in the Fc region of the IgG backbone. We wanted to achieve three things to help deliver, again, a difficult-to-beat profile. First, we wanted to extend half-life. The goal there is just to allow a lower dose, less frequent dose to get to a low-volume subcutaneous presentation. We will be starting clinical development in subQ, with plan to launch commercially with an auto-injector for at-home use. We want a half-life extension. We wanted to preserve phagocytosis. That is the mechanism whereby the approved products clear plaque. Once amyloid gets in the brain, binds to the plaque, phagocytosis by microglia is how those plaques go away. There are some other entrants in the field that have forgone phagocytosis in an effort to They have eliminated all effector function.
And while that may be a safe approach, we think it takes a lot of risk on efficacy.
Preserve phagocytosis. So, you have active Fc.
Active for phagocytosis, but then we've dialed out CDC and ADCC, two other effector functions, because we hypothesized, and proven at least in preclinical species, that that would be responsible for acute reticulocyte depletion.
Right One of the adverse consequences of trontinemab.
And so, it's that combination of half-life extension, preserving phagocytosis, and reducing CDC and ADCC that we think derive a lot of our differentiation.
Okay. On terms of the YTE modification to make it longer half-life, the benefit of that part is not necessarily to make it multi-month dosing, meaning less frequently than once a month. You do plan to do once a month. It is the ability to have the drug hang around longer, such that you think that it can be a much lower dose. Is that the point?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
